We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company¿s proprietary dually derived chitosan (DDX) platform has a high degree o... enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company¿s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company¿s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium. Show more
Ask ADVFN Intelligence (AI)
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as...
Data from pivotal cohort demonstrate compelling clinical activity, consistent with Phase 1 results Favorable tolerability profile with no drug-related discontinuations Detalimogene’s profile to...
Company remains on track to report preliminary LEGEND data in September 2024 Cash and cash equivalents of $257.7 million provide runway into 2027 enGene Holdings Inc. (Nasdaq: ENGN, or “enGene”...
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program detalimogene voraplasmid (also known as detalimogene, and...
enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for...
Ron Cooper succeeds Jason Hanson as Chief Executive Officer and Director Company also announces Dr. Raj Pruthi’s promotion to Chief Medical Officer enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or...
NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
Company announces plans for initial indication expansion for EG-70 into high-risk papillary-only NMIBC enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic...
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive...
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.57 | 8.61027190332 | 6.62 | 7.44 | 6.35 | 63109 | 6.75863622 | CS |
| 4 | 0.6 | 9.10470409712 | 6.59 | 7.85 | 4.42 | 317294 | 6.16724817 | CS |
| 12 | -1.71 | -19.2134831461 | 8.9 | 10.69 | 4.42 | 186712 | 6.72849997 | CS |
| 26 | -8.56 | -54.3492063492 | 15.75 | 16.6189 | 4.42 | 145475 | 8.37193582 | CS |
| 52 | -9.8 | -57.680988817 | 16.99 | 43 | 4.42 | 102611 | 9.55959094 | CS |
| 156 | -9.8 | -57.680988817 | 16.99 | 43 | 4.42 | 102611 | 9.55959094 | CS |
| 260 | -9.8 | -57.680988817 | 16.99 | 43 | 4.42 | 102611 | 9.55959094 | CS |
mick
2 months ago
mick
2 months ago
Monksdream
3 months ago
jump1
10 months ago
jump1
10 months ago
dinogreeves
10 months ago
dinogreeves
10 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
